Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

acute myeloid leukemia

- PMLiVE

AstraZeneca’s Baxfendy approved by US FDA for adults with uncontrolled hypertension

Hypertension affects more than 1.4 billion people worldwide and many patients remain uncontrolled despite multiple therapies

- PMLiVE

US FDA approves Taiho’s Inqovi for older adults with acute myeloid leukaemia

In 2026, an estimated 22,720 people in the US will be diagnosed with AML

- PMLiVE

Lilly’s Foundayo approved by US FDA as oral GLP-1 for weight loss

Taken at any time of the day, the oral GLP-1 is the only pill to have no food or water restrictions

- PMLiVE

J&J’s nipocalimab gets FDA Fast Track designation for lupus

The autoimmune disease affects approximately three to five million people globally

- PMLiVE

BMS’s oral AML therapy Onureg receives EU approval

Onureg is the oral version of Vidaza, two of the drugs BMS gained as part of its acquisition of Celgene in 2019

- PMLiVE

Merck strengthens KRAS stake with Taiho and Astex partnership

Partner companies could gain $2.5bn in milestone payments

- PMLiVE

Pfizer’s SMO inhibitor boosts survival in blood cancer trial

Glasdegib first to show benefit in patients with AML or MDS

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links